Wednesday, November 11, 2015 11:48:02 PM
The company chose to approach the study in a manner which has been suggested by the powers that be. The intent is to power an efficient 100 - 300 cohort P3 which will, indisputably, demonstrate the effectiveness of the treatment as real-world results are expressed in the patients and through SOA bio-markers. The clinical results of enrolles who have been treated for two years into a 8-12 year progressive disease will solidify any preclinical findings.
The implications of our sigma-1 + muscarinic activator approach are genuinely significant...make no mistake.
And 3-71 is far-more potent...as an aside...and LSB'd!
§AVXL
Recent AVXL News
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
